Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2016

View Archived Issues

Promising gene therapy for children with cerebral adrenoleukodystrophy: Clinical results on Lenti-D

AZD-5153, a novel bivalent BRD4 inhibitor with preclinical activity in hematological cancers

AstraZeneca presents novel ATM inhibitor with robust efficacy in xenograft cancer models

Hemophilia gene therapy DTX-201 optimized for IND-enabling studies

Significant efficacy seen with SER-120 nasal spray in phase III nocturia study

Bayer's ALK-1 inhibitor tested in vivo for ocular neovascularization

Immune Design and Corp-Gritstone Oncology announce cancer immunotherapy agreement

Incyte to acquire ARIAD's European operations, in-license Iglusig

Vitaeris obtains rights to Alder BioPharmaceuticals' clazakizumab

Bayer Schering Pharma discloses NADP inhibitors

Janssen Pharmaceutica patents NFkappaB-inducing kinase inhibitors

Orca Pharmaceuticals reports RORgamma antagonists

Bayer Schering Pharma patent reveals BRD4 inhibitors

CSIR discloses antimalaria compounds

NS-2 demonstrates clinical activity in phase II trial

Chiesi Farmaceutici to acquire The Medicines Co.'s non-core cardiovascular assets

Epizyme signs tazemetostat collaboration agreement

Lilly initiates phase I trial of LY-3303560 for Alzheimer's disease

BTG to acquire Galil Medical

OPKO Health and Vifor Fresenius Medical Care enter Rayaldee agreement

FDA updates ibrutinib prescribing information

Pfenex announces topline bioequivalence data for PF-708

LabCorp announces launch of Epi proColon

Phase III trial of algenpantucel-L in resected pancreatic cancer misses primary endpoint

Meiji Seika announces discontinuation of ME-3113

Epirus Biopharmaceuticals reprioritizes pipeline to focus on biosimilars for rare diseases

Cell Therapy grants Daiichi Sankyo Japan license for its heart regeneration therapy

VBI Vaccines and SciVac Therapeutics complete merger

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...